[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Views 434
Citations 0
Comment & Response
February 2017

Validation of IDSA/ATS Algorithm for Duration of Pneumonia Therapy

Author Affiliations
  • 1Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland
  • 2Division of Infectious Diseases & Infection Control Program Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
JAMA Intern Med. 2017;177(2):283-284. doi:10.1001/jamainternmed.2016.8574

To the Editor The randomized clinical trial (RCT) by Uranga et al1 in a recent issue of JAMA Internal Medicine aimed to validate the algorithm on antibiotic duration for community-acquired pneumonia (CAP) recommended by the 2007 guidelines.2 We congratulate Uranga et al on this study. It examines a timely and important issue: that limiting the duration of therapy is an understudied and underused aspect of antimicrobial stewardship. However, we have some concerns about the study’s design and conduct.